Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection
Jillian Kallman Price,1 Lynn H Gerber,1,2 Maria Stepanova,1– 3 Leyla de Avila,1 Ali A Weinstein,4 Huong Pham,1 Fatema Nader,1 Mariam Afendy,1 Kathy Terra,3 Patrick Austin,1 Wisna’odom Keo,1 Andrei Racila,1 James Michael Estep,1 Suzannah Gerber,1 Manisha Verma,1 Pegah Golabi,1 Brian P Lam,1– 3 Zobair...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-04-01
|
| Series: | International Journal of General Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/post-acute-sars-cov-2-symptoms-are-fewer-less-intense-over-time-in-peo-peer-reviewed-fulltext-article-IJGM |
| _version_ | 1797839263910330368 |
|---|---|
| author | Price JK Gerber LH Stepanova M de Avila L Weinstein AA Pham H Nader F Afendy M Terra K Austin P Keo W Racila A Estep JM Gerber S Verma M Golabi P Lam BP Younossi Z |
| author_facet | Price JK Gerber LH Stepanova M de Avila L Weinstein AA Pham H Nader F Afendy M Terra K Austin P Keo W Racila A Estep JM Gerber S Verma M Golabi P Lam BP Younossi Z |
| author_sort | Price JK |
| collection | DOAJ |
| description | Jillian Kallman Price,1 Lynn H Gerber,1,2 Maria Stepanova,1– 3 Leyla de Avila,1 Ali A Weinstein,4 Huong Pham,1 Fatema Nader,1 Mariam Afendy,1 Kathy Terra,3 Patrick Austin,1 Wisna’odom Keo,1 Andrei Racila,1 James Michael Estep,1 Suzannah Gerber,1 Manisha Verma,1 Pegah Golabi,1 Brian P Lam,1– 3 Zobair Younossi1– 3 1Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA; 2Inova Medicine, Inova Health System, Falls Church, VA, USA; 3Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA, USA; 4Department of Global and Community Health, George Mason University, Fairfax, VA, USACorrespondence: Jillian Kallman Price, Research Investigator, Outcomes Research, Beatty Liver and Obesity Research Program, Center for Integrated Research, Department of Medicine, Inova Health System, Claude Moore Health Education and Research Building, Inova Fairfax Medical Campus, 3300 Gallows Road, Falls Church, VA, 22042, USA, Tel +1-703-776-3032, Fax +1-703- 776-4386, Email Jillian.Price@inova.orgIntroduction: Many with post-acute SARS-CoV-2 (PASC) have persistent symptoms impacting physical and cognitive function, decreased health and health-related life quality. Monoclonal antibody (mAb) treatment was available to acutely infected patients which might improve these outcomes.Purpose: To compare patient perception of PASC symptoms for those receiving bamlanivimab or casirivimab and imdevimab (mAbs) to those not receiving this treatment (non-mAbs). To compare changes between these groups in symptoms, function and quality of life over a 6-month follow-up.Patients and Methods: Consented adults > 28 days post-infection with positive SARS-CoV-2 qPCR or antigen test and SARS-CoV-2 infection between March of 2020 and July of 2022 were enrolled. This prospective, repeated measure observational study reports baseline through 6-month follow-up. Extensive sociodemographic data, detailed medical history, COVID-19 symptom history, and standardized measures of well-being, depression, anxiety, stigma, cognition, symptom assessment, distress, and health status were collected.Results: 323 participants [101 mAb, 221 non-mAb, 52.7± 15.5 years, 47.7% male, body mass index (BMI) 31.4± 8.4] were analyzed. Fewer symptoms at baseline were reported in mAb versus non-mAb participants (1.06± 1.31 vs 1.78± 2.15, respectively p=0.0177) 6 months: (0.911± 1.276 mAb vs.1.75± 2.22 non-mAb, p=0.0427). Both groups showed significant within-group decreases in symptom number (52 to 21 mAb, 126 to 63 non-mAb) and symptom burden (p=0.0088 mAb, p< 0.00001 non-mAb). mAb patients had significantly shorter infection-to-baseline interval (days) (120.4± 55.3 mAb vs 194.0± 89.3 non-mAb, p< 0.00001); less frequent history of myocardial infarction (0.0 vs 3.9%, p=0.0464); headache (2.0% vs.11.8%, p=0.0046), rash (3.1% vs 9.9%, p=0.0377), and miscellaneous muscle complaints (2.0% vs 12.3%, p=0.0035), plus significantly better 6-month mood. (2.2% vs 13.2%, p=0.0390).Conclusion: mAb treated participants had reduced symptom burden and consistently reported fewer symptoms than non-mAb at all time points despite less time since acute illness. Both groups reported a statistically significant decrease in symptoms by 6-month visit with no statistically significant differences between them at follow-up.Keywords: monoclonal antibodies, patient-reported outcomes, symptom burden, recovery, COVID-19 |
| first_indexed | 2024-04-09T15:54:06Z |
| format | Article |
| id | doaj.art-7b296ee65a304f01bcfdae1ebf740166 |
| institution | Directory Open Access Journal |
| issn | 1178-7074 |
| language | English |
| last_indexed | 2024-04-09T15:54:06Z |
| publishDate | 2023-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of General Medicine |
| spelling | doaj.art-7b296ee65a304f01bcfdae1ebf7401662023-04-25T18:55:18ZengDove Medical PressInternational Journal of General Medicine1178-70742023-04-01Volume 161479149083254Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute InfectionPrice JKGerber LHStepanova Mde Avila LWeinstein AAPham HNader FAfendy MTerra KAustin PKeo WRacila AEstep JMGerber SVerma MGolabi PLam BPYounossi ZJillian Kallman Price,1 Lynn H Gerber,1,2 Maria Stepanova,1– 3 Leyla de Avila,1 Ali A Weinstein,4 Huong Pham,1 Fatema Nader,1 Mariam Afendy,1 Kathy Terra,3 Patrick Austin,1 Wisna’odom Keo,1 Andrei Racila,1 James Michael Estep,1 Suzannah Gerber,1 Manisha Verma,1 Pegah Golabi,1 Brian P Lam,1– 3 Zobair Younossi1– 3 1Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA; 2Inova Medicine, Inova Health System, Falls Church, VA, USA; 3Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA, USA; 4Department of Global and Community Health, George Mason University, Fairfax, VA, USACorrespondence: Jillian Kallman Price, Research Investigator, Outcomes Research, Beatty Liver and Obesity Research Program, Center for Integrated Research, Department of Medicine, Inova Health System, Claude Moore Health Education and Research Building, Inova Fairfax Medical Campus, 3300 Gallows Road, Falls Church, VA, 22042, USA, Tel +1-703-776-3032, Fax +1-703- 776-4386, Email Jillian.Price@inova.orgIntroduction: Many with post-acute SARS-CoV-2 (PASC) have persistent symptoms impacting physical and cognitive function, decreased health and health-related life quality. Monoclonal antibody (mAb) treatment was available to acutely infected patients which might improve these outcomes.Purpose: To compare patient perception of PASC symptoms for those receiving bamlanivimab or casirivimab and imdevimab (mAbs) to those not receiving this treatment (non-mAbs). To compare changes between these groups in symptoms, function and quality of life over a 6-month follow-up.Patients and Methods: Consented adults > 28 days post-infection with positive SARS-CoV-2 qPCR or antigen test and SARS-CoV-2 infection between March of 2020 and July of 2022 were enrolled. This prospective, repeated measure observational study reports baseline through 6-month follow-up. Extensive sociodemographic data, detailed medical history, COVID-19 symptom history, and standardized measures of well-being, depression, anxiety, stigma, cognition, symptom assessment, distress, and health status were collected.Results: 323 participants [101 mAb, 221 non-mAb, 52.7± 15.5 years, 47.7% male, body mass index (BMI) 31.4± 8.4] were analyzed. Fewer symptoms at baseline were reported in mAb versus non-mAb participants (1.06± 1.31 vs 1.78± 2.15, respectively p=0.0177) 6 months: (0.911± 1.276 mAb vs.1.75± 2.22 non-mAb, p=0.0427). Both groups showed significant within-group decreases in symptom number (52 to 21 mAb, 126 to 63 non-mAb) and symptom burden (p=0.0088 mAb, p< 0.00001 non-mAb). mAb patients had significantly shorter infection-to-baseline interval (days) (120.4± 55.3 mAb vs 194.0± 89.3 non-mAb, p< 0.00001); less frequent history of myocardial infarction (0.0 vs 3.9%, p=0.0464); headache (2.0% vs.11.8%, p=0.0046), rash (3.1% vs 9.9%, p=0.0377), and miscellaneous muscle complaints (2.0% vs 12.3%, p=0.0035), plus significantly better 6-month mood. (2.2% vs 13.2%, p=0.0390).Conclusion: mAb treated participants had reduced symptom burden and consistently reported fewer symptoms than non-mAb at all time points despite less time since acute illness. Both groups reported a statistically significant decrease in symptoms by 6-month visit with no statistically significant differences between them at follow-up.Keywords: monoclonal antibodies, patient-reported outcomes, symptom burden, recovery, COVID-19https://www.dovepress.com/post-acute-sars-cov-2-symptoms-are-fewer-less-intense-over-time-in-peo-peer-reviewed-fulltext-article-IJGMmonoclonal antibodiespatient-reported outcomessymptom burdenrecoverycovid-19 |
| spellingShingle | Price JK Gerber LH Stepanova M de Avila L Weinstein AA Pham H Nader F Afendy M Terra K Austin P Keo W Racila A Estep JM Gerber S Verma M Golabi P Lam BP Younossi Z Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection International Journal of General Medicine monoclonal antibodies patient-reported outcomes symptom burden recovery covid-19 |
| title | Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection |
| title_full | Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection |
| title_fullStr | Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection |
| title_full_unstemmed | Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection |
| title_short | Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection |
| title_sort | post acute sars cov 2 symptoms are fewer less intense over time in people treated with mono clonal antibodies for acute infection |
| topic | monoclonal antibodies patient-reported outcomes symptom burden recovery covid-19 |
| url | https://www.dovepress.com/post-acute-sars-cov-2-symptoms-are-fewer-less-intense-over-time-in-peo-peer-reviewed-fulltext-article-IJGM |
| work_keys_str_mv | AT pricejk postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT gerberlh postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT stepanovam postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT deavilal postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT weinsteinaa postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT phamh postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT naderf postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT afendym postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT terrak postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT austinp postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT keow postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT racilaa postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT estepjm postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT gerbers postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT vermam postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT golabip postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT lambp postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection AT younossiz postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection |